Financing ·
Optimi Health Corp. filed a Form 6-K containing its unaudited condensed interim consolidated financial statements and…
OPTHOptimi Health Corp.
Optimi Health Corp. filed a Form 6-K containing its unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis for the nine-month period ended June 30, 2026. The company reported revenue of $239,700 CAD, down from $490,330 in the prior-year period, alongside a net loss of $5,715,536 compared to a $2,362,664 loss previously. During the period, Optimi raised $20.7 million in gross proceeds from an underwritten public offering on the Nasdaq Capital Market and settled $450,000 in convertible debt by issuing 100,000 common shares. The filing also confirms that on May 19, 2026, the company executed a one-for-thirty reverse stock split of its outstanding securities. Optimi Health Corp. operates as a pharmaceutical drug manufacturer specializing in controlled substances, specifically MDMA and botanical psilocybin.